Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 8;5(1):71.
doi: 10.1038/s41746-022-00613-w.

Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials

Collaborators, Affiliations

Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials

Andre Esteva et al. NPJ Digit Med. .

Erratum in

  • Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials.
    Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M 3rd, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE; NRG Prostate Cancer AI Consortium; Sandler HM, Tran PT, Spratt DE, Pugh S, Feng FY, Mohamad O. Esteva A, et al. NPJ Digit Med. 2023 Feb 22;6(1):27. doi: 10.1038/s41746-023-00769-z. NPJ Digit Med. 2023. PMID: 36813827 Free PMC article. No abstract available.

Abstract

Prostate cancer is the most frequent cancer in men and a leading cause of cancer death. Determining a patient's optimal therapy is a challenge, where oncologists must select a therapy with the highest likelihood of success and the lowest likelihood of toxicity. International standards for prognostication rely on non-specific and semi-quantitative tools, commonly leading to over- and under-treatment. Tissue-based molecular biomarkers have attempted to address this, but most have limited validation in prospective randomized trials and expensive processing costs, posing substantial barriers to widespread adoption. There remains a significant need for accurate and scalable tools to support therapy personalization. Here we demonstrate prostate cancer therapy personalization by predicting long-term, clinically relevant outcomes using a multimodal deep learning architecture and train models using clinical data and digital histopathology from prostate biopsies. We train and validate models using five phase III randomized trials conducted across hundreds of clinical centers. Histopathological data was available for 5654 of 7764 randomized patients (71%) with a median follow-up of 11.4 years. Compared to the most common risk-stratification tool-risk groups developed by the National Cancer Center Network (NCCN)-our models have superior discriminatory performance across all endpoints, ranging from 9.2% to 14.6% relative improvement in a held-out validation set. This artificial intelligence-based tool improves prognostication over standard tools and allows oncologists to computationally predict the likeliest outcomes of specific patients to determine optimal treatment. Outfitted with digital scanners and internet access, any clinic could offer such capabilities, enabling global access to therapy personalization.

PubMed Disclaimer

Conflict of interest statement

A.E., D.v.d.W., and E.C. are employees at Artera. A.E., D.v.d.W., D.N., R.S., and N.N are or were employees of Salesforce.com, Inc. F.Y.F. is an advisor to and holds equity in Artera and is a consultant for Janssen, Roivant, Myovant, Bayer, Novartis, Varian, Blue Earth Diagnostics and Exact Sciences. L.S. received travel support and honorarium from Varian Medical Systems and is on the advisory board for AbbVie. M.K. received funding from Limbus AI, is a consultant for Palette Life Sciences, and is on the advisory board for AbbVie, Ferring, Janssen, and TerSera. A.E.R. is a consultant for Astellas, Bayer, Blue Earth, Janssen, Myovant, Pfizer, Progenics, and Veracyte. H.M.S. is a member of the ASTRO Board and a member of the clinical trials steering committee for Janssen. P.T.T. is a consultant for Johnson & Johnson, RefleXion Medical, Myovant, and AstraZeneca. D.E.S. is a consultant for AstraZeneca, Blue Earth, Bayer, Boston Scientific, Gammatile, Janssen, Novartis, and Varian. The remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Multimodal deep learning system and dataset.
a The multimodal architecture is composed of two parts: a tower stack to parse a variable number of digital histopathology slides and another tower stack to merge the resultant features and predict binary outcomes. b The training of the self-supervised model of the image tower stack.
Fig. 2
Fig. 2. Pathologist interpretation of self-supervised model tissue clusters.
The self-supervised model in the multimodal model was trained to identify whether or not augmented versions of small patches of tissue came from the same original patch, without ever seeing clinical data labels. After training, each image patch in the dataset of 10.05 M image patches was fed through this model to extract a 128-dimensional feature vector, and the UMAP algorithm was used to cluster and visualize the resultant vectors. A pathologist was then asked to interpret the 20 image patches closest to each of the 25 cluster centroids—the descriptions are shown next to the insets. For clarity, we only highlight 6 clusters (colored), and show the remaining clusters in gray. See Supplementary Fig. 2 for full pathologist annotation.
Fig. 3
Fig. 3. Comparison of the multimodal deep learning system to NCCN risk groups across trials and outcomes.
a Performance results reporting on the area under the curve (AUC) of time-dependent receiver operator characteristics of the MMAI (blue bars) vs. NCCN (gray bars) models, include 95% confidence intervals and two-sided p-values. Comparisons were made across 5-year and 10-year time points on the following binary outcomes: distant metastasis (DM), biochemical failure (BF), prostate cancer-specific survival (PCSS), and overall survival (OS). b Summary table of the relative improvement of the MMAI model over the NCCN model across the various outcomes and broken down by performance on the data from each trial in the validation set. Relative improvement is given by (AUCMMAI − AUCNCCN)/AUCNCCN. c Ablation study showing model performance when trained on a sequentially decreasing set of data inputs, including the pathology images only (path), pathology images + NCCN variables (path + NCCN), and pathology images + NCCN variables + age + Gleason primary + Gleason secondary (path + NCCN + 3). dh Performance comparison on the individual clinical trial subsets of the validation set—together, these five comprise the entire validation set shown in (a).

References

    1. Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Carroll PH, Mohler JL. NCCN Guidelines updates: prostate cancer and prostate cancer early detection. J. Natl Compr. Canc. Netw. 2018;16:620–623. doi: 10.6004/jnccn.2018.0036. - DOI - PubMed
    1. Ward EM, et al. Annual report to the nation on the status of cancer, featuring cancer in men and women age 20–49 Years. J. Natl Cancer Inst. 2019;111:1279–1297. doi: 10.1093/jnci/djz106. - DOI - PMC - PubMed
    1. Houshdar Tehrani MH, Gholibeikian M, Bamoniri A, Mirjalili BBF. Cancer treatment by Caryophyllaceae-type cyclopeptides. Front. Endocrinol. 2020;11:600856. doi: 10.3389/fendo.2020.600856. - DOI - PMC - PubMed
    1. Daskivich TJ, Wood LN, Skarecky D, Ahlering T, Freedland S. Limitations of the national comprehensive cancer network (NCCN®) guidelines for prediction of limited life expectancy in men with prostate cancer. J. Urol. 2017;197:356–362. doi: 10.1016/j.juro.2016.08.096. - DOI - PubMed